Financials
Financial year 2025
MRZK Pharma from Hamme (Vl.), company number BE0439203330, closed financial year 2025 with a result of € 35,837 after tax. For that financial year MRZK Pharma recorded a gross margin of € 211,421 and equity of € 556,284. Compared with financial year 2024, the result moved from € 34,155 to € 35,837. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 12, 2026.
€ 556,284
▲ 7% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 35,837
▲ 5% vs 2024
Profit after tax over the fiscal year.
€ 21,557
▼ 10% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 537,684.
People and assets in 2025
2.8
Average over the fiscal year, from the social balance sheet.
€ 162,471
▲ 26% vs 2024
€ 58,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 7,665
▼ 7% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 145,631
▼ 2% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 19,227
▲ 30% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 204,201 | € 141,379 | € 170,476 | € 211,421 | ▲ 24% |
| Profit after taxes | € 103,167 | € 62,212 | € 34,155 | € 35,837 | ▲ 5% |
| Equity | € 1,609,081 | € 486,293 | € 520,447 | € 556,284 | ▲ 7% |
| Total debts | € 143,318 | € 195,697 | € 164,097 | € 164,857 | |
| Cash | € 17,742 | € 15,554 | € 24,067 | € 21,557 | ▼ 10% |
| Retained profit | € 1,590,481 | € 467,693 | € 501,847 | € 537,684 | ▲ 7% |
| Dividend | € 0 | € 1,185,000 | € 0 | € 0 | |
| Balance sheet total | € 1,752,399 | € 681,990 | € 684,544 | € 721,142 | ▲ 5% |
| Employees (FTE) | 1.6 | 1.7 | 2.8 | 2.8 |
Key figures of MRZK Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to MRZK Pharma?
What happened at MRZK Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 35,837 (▲ 5% vs 2024). Source: NBB ↗
- Alexo BV became a director. NBB
- Sodiap BV became a director. NBB
- Deimos BV became a director. NBB
- New establishment in Hamme (Vl.). KBO
- Start of the company according to the CBE. KBO
In short
From € 103,167 profit in 2022 to € 35,837 profit in 2025.
Paid € 85,098 in corporate taxes since 2022.
Best year ever: 2022, with € 103,167 profit.
On average € 75,500 of value added per employee in 2025.
A new publication or filing at MRZK Pharma? We notify you, reason included.
Follow MRZK PharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of SODIAP comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
MRZK PharmaBehind MRZK Pharma are Sodiap BV, Alexo BV and Deimos BV. The shares are held by SODIAP (100%).
Directors
According to the 2025 annual accounts
Managing director · represented by Tom Goderis
Also active at: SDC, HC Pharma, APOTHEEK JENNE, Apotheek de Lisseweg, Apotheek Seurinck, APOTHEEK SCARPHOUT, C.E. FARMA, SANIFAR +24 more
since 2020
Chairman of the board · represented by Olivier Delaere
Also active at: SDC, HC Pharma, SODIAP, APOTHEEK JENNE, PANNOC CHEMIE, Apotheek de Lisseweg, Apotheek Seurinck, APOTHEEK SCARPHOUT +34 more
since 2022
Managing director · represented by Koenraad Clauwaert
since 2020
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Dorp 11
9220 Hamme (Vl.)
Dorp 9 -11
9220 Hamme (Vl.)
Active since 8 January 1990
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0439.203.330
- VAT number
- BE 0439.203.330
- Registered office
- Dorp 11, 9220 Hamme (Vl.)
- Names & denominations
- MRZK Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 27 December 1989
- Peppol
- Active · Active since 6 Jun 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers